Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Expert Opin Drug Saf. 2020 Mar;19(3):269-279. doi: 10.1080/14740338.2020.1733968. Epub 2020 Mar 3.
: Multiple myeloma therapy has evolved significantly over the past several decades due to the discovery of numerous novel agents. These targeted agents are highly effective but differ in their toxicity profiles. This literature review will highlight the safety of current and emerging myeloma therapy.: Therapeutic agents that are reviewed for safety and efficacy data include alkylators, proteasome inhibitors, immunomodulatory agents, monoclonal antibodies, nuclear export inhibitor, and histone deacetylase inhibitor. Emerging studies of BCL2 inhibitors and immune therapies targeting B cell maturation antigen (BCMA) such as CAR T-cell therapies, bispecific antibodies, and antibody-drug conjugates will also be reviewed.: As myeloma therapy continues to evolve, new questions arise such as sequencing of therapy, the role of stem cell transplantation, duration and appropriate choice of maintenance therapy, as well as timing of utilization of immunotherapeutic approaches. Comprehensive understanding of the toxicity profile of these agents is crucial in selecting the best therapy for patients.
: 过去几十年中，由于发现了许多新型药物，多发性骨髓瘤的治疗方法发生了重大变化。这些靶向药物非常有效，但在毒性特征上有所不同。这篇文献综述将重点介绍当前和新兴的骨髓瘤治疗方法的安全性。
: 对安全性和疗效数据进行评估的治疗药物包括烷化剂、蛋白酶体抑制剂、免疫调节剂、单克隆抗体、核输出抑制剂和组蛋白去乙酰化酶抑制剂。还将对 BCL2 抑制剂和针对 B 细胞成熟抗原 (BCMA) 的免疫疗法的新兴研究进行综述，如 CAR T 细胞疗法、双特异性抗体和抗体药物偶联物。
: 随着骨髓瘤治疗的不断发展，出现了新的问题，如治疗方案的顺序、干细胞移植的作用、维持治疗的持续时间和适当选择，以及免疫治疗方法的应用时机。全面了解这些药物的毒性特征对于为患者选择最佳治疗方法至关重要。
